Cargando…

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues

Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a sometimes neglected, yet common, sign and symptom with a profound effect on instrumental activities of daily living. The prevalence of cognitive impairment in multiple sclerosis varies across the lifespan an...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedict, Ralph H B, Amato, Maria Pia, DeLuca, John, Geurts, Jeroen J G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011205/
https://www.ncbi.nlm.nih.gov/pubmed/32949546
http://dx.doi.org/10.1016/S1474-4422(20)30277-5
_version_ 1784906338881503232
author Benedict, Ralph H B
Amato, Maria Pia
DeLuca, John
Geurts, Jeroen J G
author_facet Benedict, Ralph H B
Amato, Maria Pia
DeLuca, John
Geurts, Jeroen J G
author_sort Benedict, Ralph H B
collection PubMed
description Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a sometimes neglected, yet common, sign and symptom with a profound effect on instrumental activities of daily living. The prevalence of cognitive impairment in multiple sclerosis varies across the lifespan and might be difficult to distinguish from other causes in older age. MRI studies show that widespread changes to brain networks contribute to cognitive dysfunction, and grey matter atrophy is an early sign of potential future cognitive decline. Neuropsychological research suggests that cognitive processing speed and episodic memory are the most frequently affected cognitive domains. Narrowing evaluation to these core areas permits brief, routine assessment in the clinical setting. Owing to its brevity, reliability, and sensitivity, the Symbol Digit Modalities Test, or its computer-based analogues, can be used to monitor episodes of acute disease activity. The Symbol Digit Modalities Test can also be used in clinical trials, and data increasingly show that cognitive processing speed and memory are amenable to cognitive training interventions.
format Online
Article
Text
id pubmed-10011205
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-100112052023-03-14 Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues Benedict, Ralph H B Amato, Maria Pia DeLuca, John Geurts, Jeroen J G Lancet Neurol Review Multiple sclerosis is a chronic, demyelinating disease of the CNS. Cognitive impairment is a sometimes neglected, yet common, sign and symptom with a profound effect on instrumental activities of daily living. The prevalence of cognitive impairment in multiple sclerosis varies across the lifespan and might be difficult to distinguish from other causes in older age. MRI studies show that widespread changes to brain networks contribute to cognitive dysfunction, and grey matter atrophy is an early sign of potential future cognitive decline. Neuropsychological research suggests that cognitive processing speed and episodic memory are the most frequently affected cognitive domains. Narrowing evaluation to these core areas permits brief, routine assessment in the clinical setting. Owing to its brevity, reliability, and sensitivity, the Symbol Digit Modalities Test, or its computer-based analogues, can be used to monitor episodes of acute disease activity. The Symbol Digit Modalities Test can also be used in clinical trials, and data increasingly show that cognitive processing speed and memory are amenable to cognitive training interventions. Elsevier Ltd. 2020-10 2020-09-16 /pmc/articles/PMC10011205/ /pubmed/32949546 http://dx.doi.org/10.1016/S1474-4422(20)30277-5 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Benedict, Ralph H B
Amato, Maria Pia
DeLuca, John
Geurts, Jeroen J G
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title_full Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title_fullStr Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title_full_unstemmed Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title_short Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
title_sort cognitive impairment in multiple sclerosis: clinical management, mri, and therapeutic avenues
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011205/
https://www.ncbi.nlm.nih.gov/pubmed/32949546
http://dx.doi.org/10.1016/S1474-4422(20)30277-5
work_keys_str_mv AT benedictralphhb cognitiveimpairmentinmultiplesclerosisclinicalmanagementmriandtherapeuticavenues
AT amatomariapia cognitiveimpairmentinmultiplesclerosisclinicalmanagementmriandtherapeuticavenues
AT delucajohn cognitiveimpairmentinmultiplesclerosisclinicalmanagementmriandtherapeuticavenues
AT geurtsjeroenjg cognitiveimpairmentinmultiplesclerosisclinicalmanagementmriandtherapeuticavenues